Notably, in conditions such as ESCC, GC, and CRC, where most reports are consistent, B7H4 seems to be a better target for immunotherapy than PD-L1, already used in cancer therapies [6,20,36,37,40,41,76,82]. This evidence concerns the gene VTCN1 and gastric cancer.